Objetivo Hepatocellular carcinoma (HCC) is the sixth most common malignancy in the world. In Scotland incidence of liver cancer has increased of 60% in men from 2000 to 2010. The outcome of patients with advanced HCC remains poor. Thus, novel therapeutic approaches based on targeting oncogenic driver pathways in HCC are urgently needed, as well as informative prognostic markers that guide the use of existing and novel therapeutic strategies. Non-coding-RNAs (ncRNA) are implicated in liver carcinogenesis. Sequence conservation across species has been postulated to indicate that a given ncRNA may have a cellular function. A genome-wide survey identified 481 genomic sequences that showed 100% identity across the human, mouse and rat genomes. These ultra-conserved regions (UCR) are transcribed as ultraconserved ncRNAs (T-UCR). As they are so finely conserved we hypothesize they may have an essential role in regulating cell homeostasis and that may give rise to cancer when are aberrantly modified. In these studies we will profile the expression of T-UCR in human HCC tissues and in mouse HCC models that have genetic abnormalities similar to those found in human HCC to select the best candidate T-UCRs with a role in HCC pathogenesis and progression. In vitro analyses will be performed to characterize the transcript of T-UCR and assess the mechanism of action. We will evaluate the prognostic value of selected T-UCR by retrospectively and prospectively assessing their expression in a series of human HCC from patients who underwent radical resection or liver transplantation, in order to assess whether their expression may predict tumour recurrence. As we have in vitro data on the efficacy of anti-T-UCR, we propose to study if therapies based on the silencing of T-UCR may prevent tumour formation in animal model. These studies will provide evidence for the use of T-UCR as biomarkers and therapeutic targets in HCC. Ámbito científico medical and health sciencesclinical medicineoncologyliver cancermedical and health sciencesclinical medicinetransplantationnatural sciencesbiological sciencesgeneticsgenomesmedical and health sciencesbasic medicinephysiologyhomeostasis Programa(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Tema(s) FP7-PEOPLE-2013-CIG - Marie-Curie Action: "Career Integration Grants" Convocatoria de propuestas FP7-PEOPLE-2013-CIG Consulte otros proyectos de esta convocatoria Régimen de financiación MC-CIG - Support for training and career development of researcher (CIG) Coordinador INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG Aportación de la UE € 93 481,18 Dirección OLD BROMPTON ROAD 123 SW7 3RP London Reino Unido Ver en el mapa Región London Inner London — West Kensington & Chelsea and Hammersmith & Fulham Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Angus Bell (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (1) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo UNIVERSITY OF GLASGOW La participación finalizó Reino Unido Aportación de la UE € 6 518,82 Dirección UNIVERSITY AVENUE G12 8QQ Glasgow Ver en el mapa Región Scotland West Central Scotland Glasgow City Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Joe Galloway (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos
